Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis

Author:

Rim Chai Hong1ORCID,Cho Won Kyung2,Park Sunmin1ORCID,Yoon Won Sup1,Yang Dae Sik3

Affiliation:

1. Department of Radiation Oncology, Ansan Hospital, Gyeonggi-do

2. Samsung Medical Center, Sungkyunkwan University School of Medicine

3. Guro Hospital, Korea University School of Medicine, Seoul, Republic of Korea

Abstract

Introduction: This meta-analysis analyzed the oncologic role of local ablative treatment (LAT) in oligometastatic nonsmall cell lung cancer. Method: Pubmed, MEDLINE, Embase, and Cochrane Library were searched until October, 2022. Studies comparing LAT with standard care (control) were included. Sensitivity analyses were performed including randomized controlled studies (RCTs). Subgroup analyses were performed according to specific categories and metastatic burden. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Considering the median OS and PFS from landmark studies, 2-year OS and 1-year PFS rates were used to calculate pooled odds ratios (ORs). Results: A total of 20 studies (four RCTs) encompassing 1750 patients were included. Surgery and radiotherapy (60 and 90% of studies) were mainly used as LATs. Pooled ORs of OS and PFS were 3.492 (95% CI:2.612–4.699, P<0.001) and 3.743 (95% CI: 2.586–5.419, P<0.001), favoring LAT, respectively. Sensitivity analyses, including RCTs showed ORs of 4.111 (P<0.001) and 4.959 (P=0.001) regarding OS and PFS, favoring LCT, respectively. Pooled 1-year and 2-year OS rates were 83.8 and 58.4% in LAT arms, whereas 64.4 and 31% in control arms; pooled 1-year and 2-year PFS rates were 64.6 and 32.8% in LAT arms, and 36.1 and 10% in control arms. In subgroup analyses, the pooled ORs were 3.981 (P<0.001), 3.355 (P<0.001), and 1.726 (P=0.373) in synchronous, oligopersistence, and oligoprogression/recurrence subgroups, respectively. Regarding PFS comparison, pooled ORs were 5.631 (P<0.001), 3.484 (P<0.001), and 1.777 (P=0.07), respectively. According to metastatic burden categories, pooled ORs favored LAT arms in both analyses including low-metastatic and high-metastatic burden subgroups. Conclusion: The present study supports the role of LAT in treating nonsmall cell lung cancer oligometastasis. The oligoprogression/recurrence disease could have less LAT benefit than synchronous or oligopersistent disease.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,Surgery

Reference46 articles.

1. Emerging therapeutic agents for advanced non-small cell lung cancer;Chen;J Hematol Oncol,2020

2. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases;Pawlik;Ann Surg,2005

3. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases;Pastorino;J Thorac Cardiovasc Surg,1997

4. Surgical intervention improves survival for metastatic non-small cell lung cancer patients;Shen;Medicine (Baltimore),2016

5. Benefits of local consolidative treatment in oligometastases of solid cancers: a stepwise-hierarchical pooled analysis and systematic review;Rim;NPJ Precis Oncol,2021

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3